

## ENDURING MATERIAL LEARNER NOTIFICATION

### Med Learning Group

#### Clinical and Managed Care Considerations in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): Considerations in Addressing Underlying Inflammation

Date of CE Release: April 15, 2022

Date of CE Expiration: April 15, 2023

Location: Online

#### Acknowledgement of Financial Commercial Support

Regeneron and Sanofi Genzyme Alliance

#### Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

#### Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

#### Accreditation Statement



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

#### Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.

**NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.**

#### Objectives - After Attending This Program You Should Be Able To

1. Consider the costs and burdens of chronic rhinosinusitis with nasal polyps (CRSwNP), including pathophysiology and associated comorbidities from a managed care perspective.
2. Summarize clinical data and biomarkers concerning the use of novel antiinflammatory biologics for the management of CRSwNP, including relevant costs of care and managed care considerations.
3. Implement best practices for protocolized treatment of CRSwNP through development of individualized treatment plans with a managed care perspective.

#### Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Douglas	Cox	NA
Lisa	Crenshaw	NA
Daniel	Dasilva	NA
Chris	Drury	NA
Matthew	Frese	NA
Christina	Gallo	NA
Morgan	Kravarik	NA

Hassan	Nasir	Speakers Bureau: Astrazeneca, GSK
Jo	Shultz	NA
Geoffrey	Wall	NA
Lauren	Welch	NA

**How to Get Your Certificate**

1. Go to <http://mlg.cmecertificateonline.com/>
2. Click on the “**Enduring Clinical and Managed Care Considerations in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): Considerations in Addressing Underlying Inflammation**” link.
3. Evaluate the meeting and click the hyperlink provided on the last page to claim your credit certificate.
4. Save/Download/Print all pages of your certificate for your records.

Questions? Email [Certificate@AmedcoEmail.com](mailto:Certificate@AmedcoEmail.com)